In-stent restenosis treatment with seal-wing paclitaxel-eluting
balloon catheters

J 2021

In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters

PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA and Ota HLINOMAZ

Basic information

Original name

In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters

Authors

PLEVA, Leos (203 Czech Republic, guarantor), Pavel KUKLA (203 Czech Republic), Jana ZAPLETALOVA (203 Czech Republic) and Ota HLINOMAZ (203 Czech Republic, belonging to the institution)

Edition

cor et Vasa, AMSTERDAM, ELSEVIER SCIENCE BV, 2021, 0010-8650

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

RIV identification code

RIV/00216224:14110/21:00124158

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.33678/cor.2021.013

UT WoS

000694709000003

Keywords in English

In-stent restenosis; Paclitaxel-eluting balloon; Seal-wing PEB

Abstract

V originále

Objectives: We aimed to compare the long-term clinical outcomes of seal-wing and iopromide-coated pacli-taxel eluting balloon catheters (PEB) in the treatment of bare-metal stent restenosis (BMS-ISR). Methods: A 3-year clinical follow-up of 132 patients with BMS-ISR was performed, of whom 64 were treated with seal-wing PEB; the control group consisted of 68 patients from iopromide-coated PEB branch of the previous TIS study. The primary endpoint was the occurrence of major adverse cardiac events (MACE; cardio-vascular [CV] death, myocardial infarction [MI], or target vessel revascularization [TVR]). Results: Compared to iopromide-coated PEB, the incidence of 3-year MACE was significantly higher (40.6% vs. 19.1%; p = 0.008) in the seal-wing PEB group; a similar difference was achieved when comparing the need for TVR (26.9% vs. 8.8%; p = 0.011). The event-free survival in the iopromide-coated PEB group was signifi-cantly longer (p = 0.021). There were no differences in cardiovascular mortality (4.7% vs. 5.9%; p = 1.000), occurrence of MI (6.3% vs. 4.4%; p = 0.712), definite ST (0% vs. 2.9%; p = 0.497) or repeated MACE (4.7% vs. 1.5%; p = 0.354) between the two groups. Conclusion: Compared to iopromide-coated PEB, the use of seal-wing PEB in the treatment of BMS-ISR is as-sociated with a significantly higher 3-year incidence of MACE and TVR

Citovat

PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA and Ota HLINOMAZ. In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters. cor et Vasa. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, vol. 63, No 4, p. 442-447. ISSN 0010-8650. Available from: https://dx.doi.org/10.33678/cor.2021.013.

@article{1834325,
   author = {Pleva, Leos and Kukla, Pavel and Zapletalova, Jana and Hlinomaz, Ota},
   article_location = {AMSTERDAM},
   article_number = {4},
   doi = {http://dx.doi.org/10.33678/cor.2021.013},
   keywords = {In-stent restenosis; Paclitaxel-eluting balloon; Seal-wing PEB},
   language = {eng},
   issn = {0010-8650},
   journal = {cor et Vasa},
   title = {In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters},
   url = {https://e-coretvasa.cz/artkey/cor-202104-0003_in-stent-restenosis-treatment-with-seal-wing-paclitaxel-eluting-balloon-catheters.php},
   volume = {63},
   year = {2021}
}

TY  - JOUR
ID  - 1834325
AU  - Pleva, Leos - Kukla, Pavel - Zapletalova, Jana - Hlinomaz, Ota
PY  - 2021
TI  - In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters
JF  - cor et Vasa
VL  - 63
IS  - 4
SP  - 442-447
EP  - 442-447
PB  - ELSEVIER SCIENCE BV
SN  - 00108650
KW  - In-stent restenosis
KW  - Paclitaxel-eluting balloon
KW  - Seal-wing PEB
UR  - https://e-coretvasa.cz/artkey/cor-202104-0003_in-stent-restenosis-treatment-with-seal-wing-paclitaxel-eluting-balloon-catheters.php
N2  - Objectives: We aimed to compare the long-term clinical outcomes of seal-wing and iopromide-coated pacli-taxel eluting balloon catheters (PEB) in the treatment of bare-metal stent restenosis (BMS-ISR). Methods: A 3-year clinical follow-up of 132 patients with BMS-ISR was performed, of whom 64 were treated with seal-wing PEB; the control group consisted of 68 patients from iopromide-coated PEB branch of the previous TIS study. The primary endpoint was the occurrence of major adverse cardiac events (MACE; cardio-vascular [CV] death, myocardial infarction [MI], or target vessel revascularization [TVR]). Results: Compared to iopromide-coated PEB, the incidence of 3-year MACE was significantly higher (40.6% vs. 19.1%; p = 0.008) in the seal-wing PEB group; a similar difference was achieved when comparing the need for TVR (26.9% vs. 8.8%; p = 0.011). The event-free survival in the iopromide-coated PEB group was signifi-cantly longer (p = 0.021). There were no differences in cardiovascular mortality (4.7% vs. 5.9%; p = 1.000), occurrence of MI (6.3% vs. 4.4%; p = 0.712), definite ST (0% vs. 2.9%; p = 0.497) or repeated MACE (4.7% vs. 1.5%; p = 0.354) between the two groups. Conclusion: Compared to iopromide-coated PEB, the use of seal-wing PEB in the treatment of BMS-ISR is as-sociated with a significantly higher 3-year incidence of MACE and TVR
ER  -

PLEVA, Leos, Pavel KUKLA, Jana ZAPLETALOVA and Ota HLINOMAZ. In-stent restenosis treatment with seal-wing paclitaxel-eluting balloon catheters. \textit{cor et Vasa}. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, vol.~63, No~4, p.~442-447. ISSN~0010-8650. Available from: https://dx.doi.org/10.33678/cor.2021.013.

Detailed Information on Publication Record